- March 10, 2026– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –…
- March 3, 2026NEW YORK, March 3, 2026 – Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company pioneering the development of novel oral therapies…
- February 26, 2026– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –…
- February 17, 2026– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – –…
- February 13, 2026– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – –…
- February 4, 2026– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER…
- January 7, 2026– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by…
